Chemistry:Teniloxazine

From HandWiki
Revision as of 02:11, 9 March 2024 by WikiGary (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Teniloxazine
Teniloxazine.svg
Clinical data
Other namesY-8894
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H19NO2S
Molar mass289.39 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Teniloxazine (Lucelan, Metatone), also known as sufoxazine and sulfoxazine, is a drug which is marketed in Japan .[1] Though initially investigated as a neuroprotective and nootropic agent for the treatment of cerebrovascular insufficiency in the 1980s,[2][3][4][5][6][7][8][9] it was ultimately developed and approved as an antidepressant instead.[10] It acts as a potent norepinephrine reuptake inhibitor, with fair selectivity over the serotonin and dopamine transporters, and also behaves as an antagonist of the 5-HT2A receptor.[7][10][11]

See also

References

  1. Dictionary of pharmacological agents. CRC Press. 1997. pp. 1905. ISBN 978-0-412-46630-4. https://books.google.com/books?id=A0THacd46ZsC&pg=PA1905. Retrieved 27 October 2011. 
  2. "[Pharmacological studies on sufoxazine (Y-8894). (I) Effects on experimental amnesia in mice]" (in ja). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 85 (2): 71–7. February 1985. doi:10.1254/fpj.85.71. PMID 2859238. 
  3. "[Pharmacological studies on sufoxazine (Y-8894). (II). Anti-anoxic effect]" (in ja). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 86 (4): 323–8. October 1985. doi:10.1254/fpj.86.323. PMID 4085932. 
  4. "[Pharmacological studies on Y-8894. (III). Its effect on the abnormal electrocorticogram induced by destruction of the internal capsule]" (in ja). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 88 (4): 289–97. October 1986. doi:10.1254/fpj.88.289. PMID 3491778. 
  5. "[Pharmacological studies on Y-8894. (IV). Ameliorative effect on a cerebral energy metabolism disorder induced by KCN]" (in ja). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 88 (5): 363–7. November 1986. doi:10.1254/fpj.88.363. PMID 3817653. 
  6. "[Pharmacological studies on Y-8894. (V) Effect on learning and memory in intact and experimentally amnesic rats]" (in ja). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 89 (3): 145–53. March 1987. doi:10.1254/fpj.89.145. PMID 2884174. 
  7. 7.0 7.1 "[Pharmacological studies on Y-8894 (VI). The effect on monoamine uptake and turnover in mouse brain]" (in ja). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 90 (1): 41–9. July 1987. doi:10.1254/fpj.90.41. PMID 2443434. 
  8. "[Pharmacological studies on Y-8894. (VII). Effects on transient cerebral ischemia-induced amnesia in rats]" (in ja). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 90 (6): 321–30. December 1987. doi:10.1254/fpj.90.321. PMID 3443414. 
  9. "[Pharmacological studies on Y-8894. (VIII). Effects on learning and memory in the radial maze task in mice]" (in ja). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 92 (2): 113–8. August 1988. doi:10.1254/fpj.92.113. PMID 3224898. 
  10. 10.0 10.1 "Clinical pharmacology of a new antidepressant, Y-8894 in healthy young and elderly volunteers". British Journal of Clinical Pharmacology 23 (5): 537–43. May 1987. doi:10.1111/j.1365-2125.1987.tb03089.x. PMID 3593624. 
  11. "Therapeutic Agent for Attention-Deficit Hyperactivity Disorder - Google Patents". http://www.google.com/patents?id=UNCzAAAAEBAJ&printsec=abstract#v=onepage.